azidopine and thiazolyl-blue

azidopine has been researched along with thiazolyl-blue* in 1 studies

Other Studies

1 other study(ies) available for azidopine and thiazolyl-blue

Article	Year
Schisandrin B--a novel inhibitor of P-glycoprotein. Biochemical and biophysical research communications, 2005, Sep-23, Volume: 335, Issue:2 P-glycoprotein-mediated drug efflux is one of the major causes of the cancer multidrug resistance (MDR). Inhibition of P-glycoprotein could reverse cancer MDR. Here, we show that schisandrin B, a naturally occurring compound from Schisandra chinensis (Turcz.) Baill, bears strong potency to inhibit P-glycoprotein. Schisandrin B reversed the drug resistance of four MDR cell lines characterized with overexpression of P-glycoprotein and fully restored the intracellular drug accumulation by interacting with P-glycoprotein. Schisandrin B has a core structure of dibenzocyclooctadiene, representing a novel P-glycoprotein inhibitor. To our best knowledge, the role of schisandrin B to inhibit P-glycoprotein has not been reported. Topics: Affinity Labels; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azides; Cell Line, Tumor; Cell Proliferation; Cyclooctanes; Daunorubicin; Dihydropyridines; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Humans; Inhibitory Concentration 50; K562 Cells; Lignans; Models, Chemical; Neoplasms; Polycyclic Compounds; Protein Binding; Tetrazolium Salts; Thiazoles; Time Factors	2005

Article

Year

Schisandrin B--a novel inhibitor of P-glycoprotein.

Biochemical and biophysical research communications, 2005, Sep-23, Volume: 335, Issue:2

P-glycoprotein-mediated drug efflux is one of the major causes of the cancer multidrug resistance (MDR). Inhibition of P-glycoprotein could reverse cancer MDR. Here, we show that schisandrin B, a naturally occurring compound from Schisandra chinensis (Turcz.) Baill, bears strong potency to inhibit P-glycoprotein. Schisandrin B reversed the drug resistance of four MDR cell lines characterized with overexpression of P-glycoprotein and fully restored the intracellular drug accumulation by interacting with P-glycoprotein. Schisandrin B has a core structure of dibenzocyclooctadiene, representing a novel P-glycoprotein inhibitor. To our best knowledge, the role of schisandrin B to inhibit P-glycoprotein has not been reported.

Topics: Affinity Labels; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azides; Cell Line, Tumor; Cell Proliferation; Cyclooctanes; Daunorubicin; Dihydropyridines; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Humans; Inhibitory Concentration 50; K562 Cells; Lignans; Models, Chemical; Neoplasms; Polycyclic Compounds; Protein Binding; Tetrazolium Salts; Thiazoles; Time Factors

2005